Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.
The hypolipidemic action of fibrates has recently been shown to involve the activation of peroxisome proliferator activated receptors establishing a molecular mechanism for this class of drugs. Increasing clinical trial evidence supports the efficacy of fibrates in the treatment of dyslipoproteinemias, particularly in patients with hypertriglyceridemia and low high-density lipoproteins.
Fruchart
J C
JC
Pasteur Institute, Inserm Unit 325, Lille, France.
Brewer
H B
HB
Leitersdorf
E
E
D000818:Animals; D008078:Cholesterol, LDL / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D015248:Gemfibrozil / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006951:Hyperlipoproteinemias / Q000188:drug therapy* / Q000453:epidemiology; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D012307:Risk Factors
D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002994:Clofibrate; D015248:Gemfibrozil